FDA Determines Regulatory Review Period for EVRYSDI Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for EVRYSDI's patent extension application, submitted to the US Patent and Trademark Office (USPTO), in accordance with federal law.